Icatibant Teva B.V

Icatibant acetate, the active ingredient in Icatibant Teva B.V, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with a confirmed diagnosis.

GNH USA supplies Icatibant Teva B.V as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema.

- Acute attacks of hereditary angioedema (type I): rapid reduction of swelling and associated pain. - Acute attacks of hereditary angioedema (type II): rapid reduction of swelling and associated pain. - Hereditary angioedema (all types): immediate symptom control during an attack.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Swelling: transient local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, itching, or hives. - Anaphylaxis: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Worsening angioedema: paradoxical increase in swelling. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following precautions. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution and observe liver function tests. - Pregnancy: safety not established; weigh benefits against potential risks. - Breastfeeding: unknown safety; consider alternative therapy. - Concomitant ACE inhibitors: increased risk of angioedema; monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications; review the following.

Major Interactions (Avoid): - ACE inhibitors: heightened risk of angioedema. - Angiotensin receptor blockers: similar risk of increased swelling. - Estrogen‑containing contraceptives: may exacerbate angioedema episodes.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure and electrolyte balance. - Other bradykinin‑modulating agents: observe for additive effects on vascular permeability.